The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica
Open accessAbstract
OBJECTIVE: To describe first experiences with the integrin inhibitor natalizumab, given to patients with suspected relapsing-remitting multiple sclerosis (MS) who were later diagnosed with aquaporin 4-positive neuromyelitis optica (NMO). DESIGN: Retrospective case series. SETTING: Neurology departments at tertiary referral centers in Germany. PATIENTS: Patients with NMO who tested positive for antibodies to aquaporin 4. INTERVENTION: Treatment with natalizumab. MAIN OUTCOME MEASURES: Relapses and accumulation of disability. RESULTS: We identified 5 patients (4 female; median age, 45 years) who were initially diagnosed with MS and treated with natalizumab before diagnosis of NMO was established. Natalizumab was given as escalation therapy after failure of first- or second-line immunomodulatory therapies for MS. During natalizumab therapy (median duration, 8 infusions; range, 2-11 infusions), all 5 patients displayed persisting disease activity; a total of 9 relapses occurred (median duration to relapse, 120 days; range, 45-230 days) after the start of treatment. Four patients had an accumulation of disability and 1 patient died 2 months after cessation of natalizumab treatment. CONCLUSIONS: Our results suggest that natalizumab fails to control disease activity in patients with NMO. Neuromyelitis optica should be considered as a differential diagnosis in patients with suspected MS who are unresponsive to natalizumab therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20703 · Cited by 5,017
Self-citationA Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,574
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S., & Hinson, S. R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050304 · Cited by 2,288
The clinical course of neuromyelitis optica (Devic’s syndrome)
Wingerchuk, D. M., Hogancamp, W. F., O’Brien, P. C., & Weinshenker, B. G. (1999) · Neurology · doi:10.1212/wnl.53.5.1107 · Cited by 1,822
Barkhof, F. (1997) · Brain · doi:10.1093/brain/120.11.2059 · Cited by 1,251
Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 Expression
Pittock, S. J., Weinshenker, B. G., Lucchinetti, C. F., Wingerchuk, D. M., Corboy, J. R., & Lennon, V. A. (2006) · Archives of Neurology · doi:10.1001/archneur.63.7.964 · Cited by 701
Brain Abnormalities in Neuromyelitis Optica
Pittock, S. J., Lennon, V. A., Krecke, K., Wingerchuk, D. M., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Archives of Neurology · doi:10.1001/archneur.63.3.390 · Cited by 675
An open label study of the effects of rituximab in neuromyelitis optica
Cree, B. A. C., Lamb, S., Morgan, K., Chen, A., Waubant, E., & Genain, C. (2005) · Neurology · doi:10.1212/01.wnl.0000159399.81861.d5 · Cited by 646
Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis
Misu, T., Fujihara, K., Kakita, A., Konno, H., Nakamura, M., Watanabe, S., Takahashi, T., Nakashima, I., Takahashi, H., & Itoyama, Y. (2007) · Brain · doi:10.1093/brain/awm047 · Cited by 614
Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo
Bradl, M., Misu, T., Takahashi, T., Watanabe, M., Mader, S., Reindl, M., Adzemovic, M., Bauer, J., Berger, T., Fujihara, K., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21837 · Cited by 563
Chihara, N., Aranami, T., Sato, W., Miyazaki, Y., Miyake, S., Okamoto, T., Ogawa, M., Toda, T., & Yamamura, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017385108 · Cited by 474
Havrdova, E., Galetta, S., Hutchinson, M., Stefoski, D., Bates, D., Polman, C. H., O'Connor, P. W., Giovannoni, G., Phillips, J. T., Lublin, F. D., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70021-3 · Cited by 471
Treatment of Neuromyelitis Optica With Rituximab: Retrospective Analysis of 25 Patients
(2008) · Archives of Neurology · doi:10.1001/archneur.65.11.noc80069 · Cited by 459
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica
Jarius, S., Aboul-Enein, F., Waters, P., Kuenz, B., Hauser, A., Berger, T., Lang, W., Reindl, M., Vincent, A., & Kristoferitsch, W. (2008) · Brain · doi:10.1093/brain/awn240 · Cited by 435
Immune surveillance in multiple sclerosis patients treated with natalizumab
Stüve, O., Marra, C. M., Jerome, K. R., Cook, L., Cravens, P. D., Cepok, S., Frohman, E. M., Phillips, J. T., Arendt, G., Hemmer, B., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20858 · Cited by 434
AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance
Jarius, S., & Wildemann, B. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.72 · Cited by 423
Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6
Uzawa, A., Mori, M., Arai, K., Sato, Y., Hayakawa, S., Masuda, S., Taniguchi, J., & Kuwabara, S. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510379247 · Cited by 323
Palace, J., Leite, M. I., Nairne, A., & Vincent, A. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.188 · Cited by 322
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
Pellkofer, H. L., Krumbholz, M., Berthele, A., Hemmer, B., Gerdes, L. A., Havla, J., Bittner, R., Canis, M., Meinl, E., Hohlfeld, R., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182152881 · Cited by 296
Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica
Paul, F., Jarius, S., Aktas, O., Bluthner, M., Bauer, O., Appelhans, H., Franciotta, D., Bergamaschi, R., Littleton, E., Palace, J., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040133 · Cited by 208
Immunosuppressive therapy is more effective than interferon in neuromyelitis optica
Papeix, C., Vidal, J.-S., Seze, J. D., Pierrot-Deseilligny, C., Tourbah, A., Stankoff, B., Lebrun, C., Moreau, T., Vermersch, P., Fontaine, B., et al. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458506070732 · Cited by 204
Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis
Krumbholz, M., Meinl, I., Kümpfel, T., Hohlfeld, R., & Meinl, E. (2008) · Neurology · doi:10.1212/01.wnl.0000327671.91357.96 · Cited by 194
IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum
Shimizu, J., Hatanaka, Y., Hasegawa, M., Iwata, A., Sugimoto, I., Date, H., Goto, J., Shimizu, T., Takatsu, M., Sakurai, Y., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f8832e · Cited by 188
Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic Disease)
Weinstock-Guttman, B., Ramanathan, M., Lincoff, N., Napoli, S. Q., Sharma, J., Feichter, J., & Bakshi, R. (2006) · Archives of Neurology · doi:10.1001/archneur.63.7.957 · Cited by 174
Warabi, Y., Matsumoto, Y., & Hayashi, H. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.10.008 · Cited by 174
Ito, S., Mori, M., Makino, T., Hayakawa, S., & Kuwabara, S. (2009) · Annals of Neurology · doi:10.1002/ana.21753 · Cited by 161
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells
Kivisäkk, P., Healy, B. C., Viglietta, V., Quintana, F. J., Hootstein, M. A., Weiner, H. L., & Khoury, S. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a8266f · Cited by 147
Activation of humoral immunity and eosinophils in neuromyelitis optica
Correale, J. D., & Fiol, M. P. (2004) · Neurology · doi:10.1212/01.wnl.0000148481.80152.bf · Cited by 129
Neuromyelitis Optica Treatment: Analysis of 36 Patients
Bichuetti, D. B., de Oliveira, E. M. L., Oliveira, D. M., de Souza, N. A., & Gabbai, A. A. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.203 · Cited by 118
Occurrence of acute large and edematous callosal lesions in neuromyelitis optica
Nakamura, M., Misu, T., Fujihara, K., Miyazawa, I., Nakashima, I., Takahashi, T., Watanabe, S., & Itoyama, Y. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509103301 · Cited by 107
Bergamaschi, R., Tonietti, S., Franciotta, D. M., Candeloro, E., Tavazzi, E., Piccolo, G., Romani, A., & Cosi, V. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms988oa · Cited by 99
Efficacy and Safety of Mitoxantrone in Patients With Highly Relapsing Neuromyelitis Optica
Kim, S., Kim, W., Park, M. S., Sohn, E. H., Li, X. F., & Kim, H. J. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.322 · Cited by 98
Kalluri, S. R., Illés, Z., Srivastava, R., Cree, B., Menge, T., Bennett, J. L., Berthele, A., & Hemmer, B. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.269 · Cited by 96
Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis
Yanagawa, K., Kawachi, I., Toyoshima, Y., Yokoseki, A., Arakawa, M., Hasegawa, A., Ito, T., Kojima, N., Koike, R., Tanaka, K., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c1deb9 · Cited by 93
Interferon-β1b Treatment in Neuromyelitis Optica
Tanaka, M., Tanaka, K., & Komori, M. (2009) · European Neurology · doi:10.1159/000227277 · Cited by 76
Matiello, M. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.38 · Cited by 37
Supraspinal demyelinating lesions in neuromyelitis optica display a typical astrocyte pathology
Lee, D., Metz, I., Berthele, A., Stadelmann, C., Brück, W., Linker, R. A., Gold, R., & Schroeder, A. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01105.x · Cited by 20
Cited by
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649
in cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius, S., Ruprecht, K., Kleiter, I., Borisow, N., Asgari, N., Pitarokoili, K., Pache, F., Stich, O., Beume, L.-A., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0718-0 · Cited by 899
Self-citationToosy, A. T., Mason, D. F., & Miller, D. H. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70259-x · Cited by 617
Neuromyelitis Optica Study Group (NEMOS), Trebst, C., Jarius, S., Berthele, A., Paul, F., Schippling, S., Wildemann, B., Borisow, N., Kleiter, I., Aktas, O., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-013-7169-7 · Cited by 595
Self-citationRamanathan, S., Mohammad, S., Tantsis, E., Nguyen, T. K., Merheb, V., Fung, V. S. C., White, O. B., Broadley, S., Lechner-Scott, J., Vucic, S., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316880 · Cited by 572
Metadata
- Authors
- Kleiter, I.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2012-02-01
- Volume
- 69
- Issue
- 2
- Pages
- 239
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2079409038
- Cited by
- 294
- References
- 40
- FWCI
- 22.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.